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AbstrACt
Objectives This study examined patient adherence and 
persistence to oral bisphosphonates for the treatment of 
osteoporosis in real-world settings.
Methods A systematic review was completed according to 
the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses. Medical Literature Analysis and Retrieval 
System Online (MEDLINE), Cumulative Index to Nursing and 
Allied Health Literature (CINAHL), Allied and Complementary 
Medicine Database (AMED), Database of Abstracts of Reviews 
of Effects (DARE), Health Technology Assessment (HTA) 
and National Health Service Economic Evaluation Database 
NHS EED) databases were searched for studies published 
in English language up to April 2018. Prospective and 
retrospective observational studies that used prescription 
claim databases or hospital medical records to examine 
patient adherence and persistence to oral bisphosphonate 
treatment among adults with osteoporosis were included. The 
Newcastle–Ottawa quality assessment scale (NOS) was used 
to assess the quality of included studies.
results The search yielded 540 published studies, of 
which 89 were deemed relevant and were included in 
this review. The mean age of patients included within 
the studies ranged between 53 to 80.8 years, and the 
follow-up varied from 3 months to 14 years. The mean 
persistence of oral bisphosphonates for 6 months, 1 year 
and 2 years ranged from 34.8% to 71.3%, 17.7% to 
74.8% and 12.9% to 72.0%, respectively. The mean 
medication possession ratio ranged from 28.2% to 84.5%, 
23% to 50%, 27.2% to 46% over 1 year, 2 years and 3 
years, respectively. All studies included scored between 6 
to 8 out of 9 on the NOS. The determinants of adherence 
and persistence to oral bisphosphonates included 
geographic residence, marital status, tobacco use, 
educational status, income, hospitalisation, medication 
type and dosing frequency.
Conclusions While a number of studies reported high 
levels of persistence and adherence, the findings of this 
review suggest that patient persistence and adherence 
with oral bisphosphonates medications was poor and 
reduced notably over time. Overall, adherence was 
suboptimal. To maximise adherence and persistence to 
oral bisphosphonates, it is important to consider possible 
determinants, including characteristics of the patients.
IntrOduCtIOn 
Osteoporosis is a chronic global health 
condition, characterised by low bone density 
and bone structure deterioration.1 About 
a third of men and more than half of all 
women experience osteoporosis during their 
lives.2 Moreover, evidence suggests that frac-
ture-related mortality rate is higher in men 
than women.3 The first sign of osteoporosis 
is often a fracture of the wrist, hip and spine. 
Osteoporotic fractures can lead to long-term 
problems such as chronic pain, long-term 
disability and even death.4 The long-term 
problems of osteoporosis may also lead to a 
substantial economic burden on individuals, 
health systems and society. Osteoporosis is a 
common disease in the USA, and more than 
1.5 million osteoporosis-related fractures 
occur each year.5 For example, the findings 
of a study of osteoporosis-related fractures in 
the USA indicated that patients with a diag-
nosis of osteoporosis and concurrent frac-
ture ($15,942) had more than two times the 
annual healthcare expenditure, compared 
with patients with osteoporosis without a 
fracture ($6,476).5 The total cost estimates 
for the treatment of osteoporosis and subse-
quent care in the USA was around $17 billion 
in 2003 and this is expected to increase by 
strength and limitation of this study
 ► This review only included prospective and retro-
spective observational studies that derived objective 
prescription claim data from outside clinical trial set-
tings, to better reflect real-world adherence and per-
sistence to oral bisphosphonates for the treatment 
of osteoporosis.
 ► This review was able to derive persistence and 
adherence data from 89 observational studies per-
formed within 15 different countries,
 ► The calculation of persistence and adherence across 
the included studies were heterogeneous. As a re-
sult, it was not possible to directly compare these 
studies via meta-analysis.
 ► The review did not collect self-reported patient data. 
This data may have given further insight as to the 
determinants of persistence and adherence among 
patients with osteoporosis.
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50% in 2025.6 7 The majority of this cost is spent on acute 
surgical and medical management, and subsequent 
rehabilitation.6 
Bisphosphonate medications for osteoporosis have 
been shown to increase bone strength and reduce frac-
ture risk and can be administered orally or intravenously 
across a wide range of doses and dosing intervals.8 9 
Bisphosphonate treatments such as etidronate, alendro-
nate, ibandronate, risedronate and zoledronic acid are 
able to prevent vertebral fractures more than placebo.10 
Prevention can be classified as primary or secondary. 
Primary prevention attempts to protect individuals 
against the onset of osteoporosis, whereas secondary 
prevention treats individuals living with the disease.11 
Treatments such as alendronate, risedronate and other 
oral medications such as oestrogen can prevent hip frac-
tures more than placebo. Patients treated with alendro-
nate and zoledronic acid had better efficacy in preventing 
hip fracture. On the other hand, zoledronic acid was 
reported to lead to an increased risk of adverse events 
than alendronate and placebo.12 The clinical issues that 
should be considered when treating patients with oste-
oporosis using bisphosphonates include: the choice of 
which type of bisphosphonates to use, monitoring to 
assure the medication is taken correctly, determining the 
time when these medications should be discontinued 
and the management of their side effects.13
Patient persistence and adherence to oral bisphos-
phonates can be assessed using real-world data. This 
can be derived from electronic health records, product 
and disease registries, claims and billing data and data 
gathered through personal devices.14 The International 
Society for Pharmacoeconomics and Outcomes Research 
defines persistence as the accumulation of time from 
initiation to discontinuation of therapy.15 Adherence/
compliance was defined as the extent to which a patient 
acts in accordance with the prescribed interval and dose 
as well as dosing regimen. Poor persistence and adher-
ence to bisphosphonate therapy can significantly increase 
the risk of fracture and overall burden of osteoporosis.12 
Thus it is important to quantify the prevalence of this in 
wider populations and consider potential factors that may 
influence this, such as patient characteristics.
Although previous systematic reviews have included 
some real-world data, the studies were not assessed 
for quality and did not examine the potential determi-
nants of adherence and persistence.16 17 To the authors’ 
knowledge, there is no contemporary review that focuses 
on oral bisphosphonate medication adherence and 
persistence among patients with osteoporosis in the real-
world. Understanding patient persistence and adherence 
to oral bisphosphonates and their determinants may be 
used to reduce the risk of fractures in the treatment of 
osteoporosis.1 Therefore, this current systematic review 
addresses two objectives. First, it summarises patient 
persistence and adherence to oral bisphosphonates in 
real-world settings. Second, it identifies determinants that 
may affect real-world adherence and persistence.
MethOds
This systematic review was conducted in accordance to 
the Preferred Reporting Items for Systematic Reviews 
and Meta-Analysis guideline, a technique that addresses 
the eligibility, data sources, selection of studies, data 
extraction and data analysis.18 The review was regis-
tered on PROSPERO, with registration number CRD: 
42017059894.
data sources
We searched the Allied and Complementary Medicine 
Database, Cumulative Index to Nursing and Allied Health 
Literature, MEDLINE; Database of Abstracts of Reviews 
of Effects, Health Technology Assessment database and 
the Centre for Reviews and Dissemination database up 
to April 2018. The search terms used were persist* OR 
adher* OR non-adher* OR complian* OR discontinu* 
OR prescri* OR pattern* OR gap* (TITLE) AND Osteo-
poro* OR Osteopen* OR (Bone AND loss) OR Alendron* 
OR Etidron* OR Ibandron* OR Risedron* OR bisphos-
phonat* (TITLE). All search results were exported into 
EndNote Web (Thomas Reuter, CA, USA) bibliography 
software.
Inclusion criteria
Prospective and retrospective observational studies that 
used prescription claims databases or patient electronic 
medical records or to investigate persistence and adher-
ence to oral bisphosphonate medications in the treat-
ment of osteoporosis or osteopenia in human adults 
were included. Eligible studies were required to have an 
abstract and article published in the English language, 
within a peer-reviewed source. Studies conducted in 
any geographical location were permitted. Randomised 
controlled trials (RCTs), systematic reviews, narrative 
literature reviews and conference papers were excluded. 
Further exclusion criteria were as follows; abstract unavail-
able, studies not yet fully completed, single case studies/
reports, observational studies drawing persistence/adher-
ence data from patient or general practitioner survey, 
prospective studies designed to observe changes in adher-
ence via the introduction of a non-typical intervention or 
adjunct and studies containing patients aged <18 years.
study selection
Duplicates were removed electronically and manually. 
Two independent researchers (PS and TG) were involved 
in screening the title and abstract of each study. Full-text 
articles were obtained and were excluded if they did not 
meet the inclusion criteria. Any disagreement in study 
selection was resolved through discussion and consulta-
tion with other members of the project team (GY and FF), 
where necessary. During screening, open-label extension 
studies of RCTs were excluded. It was considered that this 
design may not generate data that truly reflected a real-
world pattern of persistence and adherence. Studies using 
data from electronic medical records, outside of addi-
tion to large-scale databases were also included provided 
 o
n
 16 April 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-027049 on 14 April 2019. Downloaded from 
3Fatoye F, et al. BMJ Open 2019;9:e027049. doi:10.1136/bmjopen-2018-027049
Open access
persistence and adherence data were determined from 
prescription claims data rather than extracted from 
supplemental patient interviews, patient-supplied pill 
counts or subjective questionnaires. The literature search 
was supplemented by screening the reference lists of 
included articles for further eligible studies.
data extraction and study quality assessment
Determinants (factors that may affect or be associated 
with) persistence or adherence were extracted from 
eligible studies, including patient characteristics such as 
age and sex, medication, population location, time-frame 
of data collection and length of follow-up. The quality 
of the studies was assessed using the Newcastle–Ottawa 
quality assessment scale (NOS) for cohort studies.19 
The NOS contains eight items, categorised into three 
dimensions including selection and comparability. The 
maximum score of NOS is nine. However, some questions 
within the NOS were not applicable across the eligible 
studies dependent on their study design. In this instance, 
authors determined and adjusted the NOS score to 
account for this, rating studies only on the number of 
questions that were applicable and relevant.
data analysis
A descriptive analysis of extracted results is presented. 
No meta-analysis was carried out due to heterogeneity of 
reporting methodologies and calculations of adherence 
and persistence across studies.
Patient and public involvement
Patients and the general public were not involved in this 
study.
results
The literature search identified 540 potential articles, 
of which 517 were remained after the removal of dupli-
cates. After the titles and abstracts of these publications 
were screened, 143 references were identified as poten-
tially relevant and retrieved in full text. Of these, 89 were 
included in review (figure 1). The methodological quality 
of the included studies is presented (table 1). All the 
included studies scored between six to eight on the NOS.
The geographical location of the studies included 
were: USA (n=37), Canada (n=7), UK (n=6), Nether-
lands (n=6), Denmark (n=5), Italy (n=5), Germany 
Figure 1 The preferred reporting for systematic reviews and meta-analyses diagram representing the systematic literature 
search.94
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Table 1 Summary of studies included in this review
Reference Type of database Country
Time frame of data 
collection Length of follow-up Adjusted NOS scores
Abrahamsen29 National prescription Denmark 1995 to 2007 10 years 6/6
Blouin et al30 Régie de l’asssurance 
maladie du Québec
Canada 2002to 2004 2 years 8/8
Blouin et al20 Régie de l’asssurance 
maladie du Québec
Canada 1998 to 2001 & 
2000 to 2004
1 year 6/6
Brankin et al31 General practice research 
database IMS disease 
analyser 
UK 2001 to 2004 1 year 6/6
Doctors independent network 
database
Briesacher et al32 MarketScan research 
databases
USA 2000 to 2004 1 to 3 years 6/6
Briesacher et al33 MarketScan commercial 
claims and encounters and 
Medicare
N/A 2001 to 2006 1 year 6/6
Burden et al34 Ontario drug benefit 
database
Canada 1996 to 2009 1 to 9 years 6/6
Burden et al35 Ontario drug benefit 
database
Canada 2001 to 2012 1 year 6/6
Cadarette et al21 Pennsylvania pharmaceutical 
assistance contract
USA 1995 to 2005 6 months 6/6
Carbonell-Abella et 
al22
Sistema d‘informacio per 
al desenvolupament de 
la investigacio en atencio 
primaria
Spain 2007 to 2010 1 year 8/8
Cheen et al36 CITRIX patient record 
management system and 
MAXCARE prescription 
record system, Singapore 
General Hospital
Singapore 2007 to 2008 2 years 6/6
Cheng et al23 Chang-Gung Memorial 
Hospital, Kaohsiung Medical 
Centre
Taiwan 2001 to 2007 2 years 8/8
Colombo and 
Montecucco37
Aziende sanitarie locali Italy 2008 to 2008 34 months 6/6
Copher et al38 Administrative claims USA 2002 to 2006 1 year 8/8
Cotté et al39 Thales longitudinal 
prescription
France 2007 to 2008 1 year 8/8
Cramer et al40 De-identified healthcare 
claims
USA 1997 to 2002 1 year 8/8
Cramer et al41 Integrated Healthcare 
Information Services Inc.
USA 1997 to 2003 1 year 6/6
General practice research 
database
UK 2001 to 2005
Thales France 2000 to 2004 8/8
Curtis et al42 Linked enrolment, outpatient 
encounter, pharmacy and 
procedural billing
USA 2001 to 2004 39 months
Curtis et al43 Unidentified administrative 
claims
USA 1998 to 2005 3 years 6/6
Curtis et al44 Unidentified administrative 
claims
USA 1998 to 2005 3 years 6/6
Curtis et al45 Unidentified administrative 
claims
USA 1998 to 2005 1 year 6/6
Devine et al46 Pharmacy data transaction 
service data warehouse
USA 2006 to 2008 1 year 8/8
Continued
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Reference Type of database Country
Time frame of data 
collection Length of follow-up Adjusted NOS scores
Devold et al47 Norwegian prescription 
database
Norway 2005 to 2009 5 years 8/8
Downey et al24 National administrative 
claims
USA 2001 to 2003 1 year 6/6
Dugard et al48 An unidentified database of 
GP records
UK 1996 to 2002 5 years 6/6
Ettinger et al49 A large database was 
accessed through
USA 2002 to 2003 1 year 6/6
Feldstein et al50 Undefined health 
maintenance organisation
USA 1996 to 2006 2.7 years 6/6
Gallagher et al51 General practice research 
database
UK 1987 to 2006 2.3 years 8/8
Gold et al52 IMS longitudinal prescription USA X to 2005 6 months 8/8
Gold et al53 Unidentified pharmacy claims USA 1996 to 2003 2 years 6/6
Gold et al54 IMS longitudinal prescription USA 1996 to 2003 1 year 8/8
Hadji et al55 IMS disease analyser patient Germany 2004 to 2007 2 years 6/6
Hadji et al25 Techniker krankenkasse Germany 2006 to 2009 2 years 6/6
Hadji et al56 IMS disease analyser patient Germany 2001 to 2010 1 year 6/6
Halpern et al26 Unidentified administrative 
claims
USA 2002 to 2006 18 months 8/8
Hansen et al27 Danish national registers Denmark 1996 to 2006 5.2 years 6/6
Hansen et al57 Veteran affairs pharmacy 
service records
USA 2000 to 2004 2 years 8/8
Hawley et al58 Sistema d‘informaciό per 
al desenvolupament de 
l‘investigaciό en atenciό 
primaria
Spain 2006 to 2007 6 months 6/6
Hoer et al59 Claims database of a 
statutory sickness fund
Germany 2000 to 2004 2 years 6/6
Ideguchi et al60 Yokohama City University 
Medical Centre
Japan 2000 to 2005 5 years 6/6
Iolascon et al28 Unidentified administrative 
prescription database 
campania
Italy 2008 to 2010 1 year 6/6
Jones et al61 Ontario Drugs Database and 
Brogan Inc. private payer 
database
Canada 2003 to 2006 1 year 6/6
Kamatari et al62 Pharmacy prescription 
database
Japan 2000 to 2005 4 years 6/6
Kertes et al63 Maccabi healthcare services 
database
Israel 2003 to 2004 1 year 6/6
Kishimoto and 
Machara64
Platform for clinical 
information statistical 
analysis database
Japan 2006 to 2014 8 years 6/6
Lakatos et al65 National health insurance 
fund administration
Hungary 2004 to 2013 2 years 6/6
Landfeldt et al66 Swedish prescribed 
drug register
Sweden 2005 to 2009 4 years 6/6
LeBlanc et al67 Kaiser Permanente 
Northwest
USA 1997 to 2011 5 years 6/6
Li et al68 General practice research 
database
UK 1995 to 2008 5 years 6/6
Lin et al69 Unidentified health insurance 
database
Taiwan 2003 to 2006 1 year 6/6
Table 1 Continued 
Continued
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Reference Type of database Country
Time frame of data 
collection Length of follow-up Adjusted NOS scores
Lo et al70 Kaiser Permanente of 
Northern California
USA 2002 to 2004 1 year 8/8
Martin et al71 HealthCore integrated 
research database
2005 to 2007 3 years 8/8
McCombs et al72 Unidentified health insurance 
company, California
USA 1998 to 2001 1 year 6/6
Modi et al73 InVision data mart database USA 2002 to 2009 1 year 6/6
Modi et al74 InVision data mart database USA 2001 to 2010 2 years 6/6
Modi et al 75 Humana administrative 
health claims database
USA 2007 to 2013 1 year 6/6
Netelenbos et al76 IMS health longitudinal 
prescription database
Netherlands 2007 to 2008 1 year 6/6
Olsen et al77 The Danish national 
prescription register
Denmark 1997 to 2006 2 years 8/8
Papaioannou et al78 The Canadian database of 
osteoporosis and osteopenia
Canada 1990 to 2001 3 years 8/8
Patrick et al79 Medicare and the 
Pennsylvania pharmaceutical 
assistance contract for the 
elderly
USA 1996 to 2005 6 months 6/6
Penning-van Beest 
et al80
PHARMO record linkage 
system
Netherlands 2000 to 2003 1 year 6/6
Penning-van Beest 
et al81
PHARMO record linkage 
system
Netherlands 1999 to 2004 1 year 6/6
Penning-van Beest 
et al82
PHARMO record linkage 
system database
Netherlands 1999 to 2004 1 year 8/8
Rabenda et al83 Belgian national social 
security institute
Belgium 2001 to 2004 1 year 8/8
Recker et al84 NDC health database USA 2002 to 2003 1 year 6/6
Reynolds et al85 Kaiser Permanente Southern 
California
USA 2009 to 2011 1 year 6/6
Richards et al86 Veterans affairs rheumatoid 
arthritis registry
USA 39.2 months 8/8
Rietbrock et al87 General practice research 
database
UK 1 year 6/6
Roerholt et al88 National hospital discharge 
register and Danish national 
prescriptions database, 
Denmark
Denmark 1997 to 2004 9 years 6/6
Roughead et al89 Department of veterans’ 
affairs
Australia 2001 to 2007 6/6
Sampalis et al90 Ontario ministry of health and 
long-term care databases
Canada 1996 to 2009 14 years 6/6
Scotti et al91 Healthcare utilisation 
databases, Lombardy
Italy 2003 to 2010 5.3 years 8/8
Sheehy et al92 Régie de l’assurance maladie 
du Québec databases
2002 to 2007 1 year 6/6
Siris et al93 MedStat MarketScan 
commercial claims and 
encounters and Medicare 
databases
USA 1999 to 2003 2 years 6/6
Siris et al94 The MarketScan commercial 
claims and encounters and 
Medicare supplemental 
and coordinator of benefits 
databases
USA 2001 to 2008 2.4 years 6/6
Table 1 Continued 
Continued
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(n=5), Japan (n=3), Taiwan (n=3), Spain (n=2), France 
(n=2) and single studies from Singapore, Norway, 
Israel, Hungary, Sweden, Belgium and Australia (see 
table 1). The mean age of patients included within the 
studies ranged between 53 to 80.8 years and the length 
of follow-up ranges between 3 months and 14 years. The 
length of follow-up of the included studies could be strat-
ified to 6 months (n=4), 1 year (n=37), 2 years (n=16) 
and ≥3 years (n=32).
The medications included in this review as primary or 
secondary prevention in the treatment of osteoporosis 
are alendronate, etidronate, risedronate, ibandronate, 
clodronate, zoledronate, alendronate +vitamin D and 
risedronate +calcium. Some of the included studies also 
looked at pamidronate and raloxifene.20–28 In order to 
measure the persistence and adherence of patients to 
these medications the included studies have used different 
techniques.20–108 Persistence was measured based on the 
length of treatment without a gap in refills (table 2). The 
permissible gap between medication refills the included 
studies used was typically 30 days, and sometime 60 or 
90 days. On the other hand, adherence was measured by 
calculating the medication possession ratio (MPR),20 23–25 
29 32 33 36–48 50 52 54 55 57 59 64 67 69–71 74–77 81–84 87 90 93–95 97 98 101 104 
105 108 and proportion of days covered (PDC).21 35 79 91 105 
MPR means the number of days’ supply of medication 
received divided by the length of the follow-up period.109
Persistence
Sixty studies assessing persistence using real-world data 
from 4 070 739 patients were identified (table 2). The 
overall mean persistence of oral bisphosphonates at 
6 months,39 40 42 52 58 61 65 68 74 76 78 83 90 92 104 1 year,21–25 28 31 
34–36 39–42 48 49 51 53 55 56 59–68 70 78 80 83 87 90 92 95 99 100 103 105 108 2 
years25 27 30 34 36 42 48 53 56 59 60 64–66 68 90 94 100 103 and 3 years 
ranged from 34.8% to 71.3%, 17.65% to 74.80%, 12.9% 
to 60.60% and 21.0% to 40.0% respectively (figure 2). 
The 6 month persistence of ibandronate,39 52 65 68 alendro-
nate42 61 65 68 78 92 and risedronate,39 52 61 65 68 92 ranged from 
29% to 57.3%, 45.5% to 79% and 46.8% to 77%, respec-
tively. Thirteen studies reported 1 year persistence data 
for alendronate (12.6% to 70.1%),22 24 28 42 62 65 66 68 78 92 99 
Reference Type of database Country
Time frame of data 
collection Length of follow-up Adjusted NOS scores
Soong et al95 National health insurance 
research database
Taiwan 2004 to 2006 1 year 6/6
Ström96 Swedish prescribed drug 
register
Sweden 2005 to 2009 4 years 6/6
Sunyecz et al97 Thomson healthcare, 
MarketScan commercial 
claims and encounters 
and MarketScan 
Medicare, supplemental 
and coordination of benefits 
databases
USA 2000 to 2002 3 years 6/6
Tafaro et al98 General practitioner 
databases
Italy 2001 to 2007 300 days 6/6
Van Boven et al99 The InterAction database Netherlands 2003 to 2011 1 year 6/6
Van den Boogaard et 
al100
PHARMO record linkage 
system
Netherlands 1996 to 2003 3 years 6/6
Wang et al101 Centres for Medicare and 
Medicaid services
USA 2006 to 2010 5 years 6/6
Weiss et al102 IMS longitudinal prescription 
database
2004 to 2006 1 year 6/6
Weycker et al103 PharMetrics patient-centric 
database
USA 1998 to 2003 5.5 years 6/6
Weycker et al104 Health alliance plan of Henry 
Ford Health System
USA 2002 to 2007 27.1 months 6/6
Yeaw et al105 PharMetrics patient-centric 
database
USA 2005 to 2005 1 to 2 years 6/6
Yood et al106 Unidentified health 
maintenance organisation
USA 1998 to 1999 18 months 6/6
Zambon et al107 Health services databases of 
Lombardy
Italy 2003 to 2005 3 years 6/6
Ziller et al108 IMS longitudinal prescription 
database
Germany 2007 to 2009 1 year 6/6
GP, general practitioner; NOS, Newcastle–Ottawa quality assessment scale; N/A, not reported.
Table 1 Continued 
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108 risedronate (15.8% to 68.0%)22 24 28 42 54 61 63 65 68 92 100 
108 and ibandronate (18.4% to 58.5%)%).22 28 54 65 68 99 108
Out of 19 studies,25 27 30 34 36 42 48 53 56 59 60 64–66 68 90 94 100 
103 that reported the 2 year persistence of oral bisphos-
phonates, more than 70% of them found the proportion 
of patients persistent to be <30%. A 3 year persistence of 
21% and 40% was reported by two studies.97 99
Adherence
We identified 55 studies that measured adherence based 
on real-world data from 4 033 731 patients in different 
countries (table 3). The minimum length of follow-up 
period used in the included studies to measure MPR and 
PDC was 3 months. The 3 month follow-up study reported 
the proportion of adherent patients to alendronate and 
risedronate as 72.8% (daily) and 80% (weekly).80 Few 
studies reported MPR that ranged between 55.6% and 
90% for 6 months follow-up (table 3).21 52 59 79 Across all 
studies that reported MPR at 1 year, the proportion of 
patients adherent to medication varied from 31.7% to 
72.0%.23 24 27 28 32–34 36 38–42 44 46 48 53 59 61 64 69 71 73 74 76 80 84 94 
95 105 108
Across six studies adherence at 2 years was less than 
that of adherence at 1 year, ranging from 34.5% to 
47.9%.23 32 43 59 71 74 Parallel to this, six studies reported the 
proportion of patients who achieved MPR ≥80% at 3 years 
varied between 23% and 47.9%.29 32 43 44 48 71 Overall, 
adherence rates to oral bisphosphonates reduced over-
time within and across studies.
determinants of persistence and adherence
Out of the 89 studies, 55 reported at least one poten-
tial determinant of persistence and adherence to oral 
bisphosphonates (online supplementary file 1). The 
potential determinants of persistence and adherence 
reported in the studies included geographic residence,30 
prior bone mineral density (BMD) test,20 30 39 48 70 
chronic disease score,30 hospitalisation,30 51 80 94 medi-
cation type and frequency,22 24 31 38–43 45 46 49 51–54 63 64 78 
80 81 83 86 91 92 97 99 100 102 103 107 108 age,27 36 38 40 42 46–49 51 53 
61 63 69 70 73 76 77 80 81 87 89 91 93 94 99 102 104 107 history of frac-
tures,36 51 59 72 73 77 81 88 94 103 race/ethnicity38 and number 
of co-medication.40 69 77 88 91 93 In addition to these, 
glucocorticoid,43 70 100 gender,51 60 62 69 76 77 88 92 99 educa-
tion status,47 77 86 income,47 marital status,47 history of R
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Figure 2 Frequency for reported range of mean persistence 
per length of treatment.
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Table 3 Adherence data for osteoporosis medications
Reference Medication
Population (mean 
age) Compliance, mean MPR
Abrahamsen29 Alendronate 58 674 (n/a) <5 years 5 to 10 years >10 years
Etidronate Alendronate (92%) Alendronate (84%) Alendronate (76%)
Ibandronate Etidronate (92%) Etidronate (89%) Etidronate (88%)
Risedronate Ibandronate (81%) Ibandronate (75%) Ibandronate (70%)
Clodronate Risedronate (91%) Risedronate (80%) Risedronate (75%)
Blouin et al20 Alendronate 15 027 (76.6) 69.7%±34.8%
Risedronate
Briesacher et al32 Alendronate, risedronate 17 988 (61.4) At 1 year, At 2 years, At 3 years,
42.9% (MPR ≥80%) 34.5% (MPR ≥80%) 30.6% (MPR ≥80%)
12.6% (MPR 60% to 
79%)
10% (MPR 60% to 
79%)
10% (MPR 60% to 
79%)
10.4% (MPR 40% to 
59%)
7.7% (MPR 40% to 
59%)
7.2% (MPR 40% to 
59%)
13.8% (MPR 20% to 
39%)
8.2% (MPR 20% to 
39%)
7.8% (MPR 20% to 
39%)
20.4% (MPR <20%) 38.7% (MPR <20%) 44.2% (MPR <20%)
Briesacher et al33 Alendronate, ibandronate, 
risedronate
61 125 (62.1) At 1 year (monthly 
medication),
At 1 year (weekly 
medications)
At 1 year (daily 
medication)
49% (MPR≥80%) 49% (MPR ≥80%) 23% (MPR ≥80%)
11% (MPR 60% to 
79%), 11% (MPR 40% 
to 59%), 13% (MPR 
20% to 39%)
14% (MPR 60% to 
79%)
8% (MPR 60% to 79%)
16% (MPR <20%) 9% (MPR 40% to 59%) 11% (MPR 40% to 
59%)
14% (MPR 20% to 
39%)
16% (MPR 20% to 
39%)
14% (MPR <20%) 42% (MPR <20%)
Burden et al35 Alendronate, etidronate, 
risedronate
337 329 (75.7) 70%*
Cadarette et al21 Alendronate, risedronate 20 205 (79) 49.8% (PDC ≥80%); 
14.5% (PDC 51% 
to 79%); 35.7% 
(PDC ≤50%)
Cheen et al36 Alendronate, risedronate 798 (68.5) 78.90%
Cheng et al23 Alendronate 1745 (68.1) At 1 year; 61.9% At 2 years, 47.9% 
(MPR ≥80%)
(MPR >80%)
Colombo and 
Montecucco37
Generic alendronate, 
branded alendronate
20 711 (73) 69% to 74%
Copher et al38 Alendronate, 
ibandronate, risedronate
1587 (62.3) 48.70% (95% CI 46.2 
to 51.2)
Cotté et al39 Alendronate, risedronate 2990 (69.9) 79.4% (95% CI 78.2 
to 80.5) (weekly 
medications)
Ibandronate 84.5% (95% CI 83.1 
to 85.9) (monthly 
ibandronate)
Cramer et al40 Alendronate, risedronate, 
ibandronate
2741 (n/a) 60.60%
Cramer et al41 Alendronate, risedronate 2741(73) 64%
Curtis et al42 Alendronate, risedronate 1158 (53) 73%
Curtis et al43 Alendronate, risedronate 25 446 (n/a) At 2 years, At 3 years,
Achieved MPR >80% = 
29.4%
Achieved MPR >80% = 
27.2%
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Reference Medication
Population (mean 
age) Compliance, mean MPR
Achieved MPR <50% = 
34.9%
Achieved MPR <50% = 
39.4%
Curtis et al45 Alendronate 101 038 (n/a) Achieving MPR >80% 
= 44%
Ibandronate, risedronate
Devine et al46 Alendronate, ibandronate, 
risedronate
22 363 (n/a) 62%
Devold et al47 Alendronate 7610 (66.6) Achieving MPR ≥80% 
= 45.5%
Downey et al24 Alendronate, risedronate 10 566 (66.4) 60.7% (alendronate)
58.4% (risedronate)
Dugard et al48 Not stated 254 (76.7) At 1 year, At 3 years, At 5 years, achieving 
MPR ≥80% = 23%
Achieving MPR ≥80% 
= 44%
Achieving MPR ≥80% 
= 42%
Feldstein et al50 Alendronate, ibandronate, 
risedronate
1829 (72) 60%
Gold et al52 Ibandronate, risedronate 234 862 (n/a) 83.3% (risedronate) 79% (risedronate)
78.5% (ibandronate)
Gold et al 53 Ibandronate, risedronate 263 383 (66.21) 74.68% (ibandronate)
80.15% (risedronate)
Hadji et al55 Alendronate, clodronate, 
etidronate, risedronate
4147 (n/a) Achieving MPR ≥80% 
= 66.3%
Achieving MPR <80% 
= 22.7%
Halpern et al26 Alendronate, ibandronate, 
risedronate
21 655 (63.3) At 6 months, At 18 months,
76% (commercially 
insured)
59% (commercially 
insured)
68% (Medicare 
advantage)
53% (Medicare 
advantage)
Hansen et al57 Alendronate 198 (71) At 12 months, At 2 years,
Achieving MPR ≥80% 
= 59%
Achieving MPR ≥80% 
= 54%
Hoer et al59 Alendronate, etidronate, 
risedronate
4451(n/a) At 6 months, At 1 year,
Achieving MPR ≥80% 
= 58.6%
Achieving MPR ≥80% = 
46.25%
Kishimoto and 
Machara64
Not stated 12 230 (62) At 1 year, At 5 years,
38.6% (daily) 20.8% (daily)
70.6% (weekly) 60.9% (weekly)
77.7% (monthly)
LeBlanc et al67 Not stated 14 674 (71) 94%
Lin et al69 Alendronate 8936 (74) 60.20%
Lo et al70 Alendronate 13 455 (68.8) 93%
Martin et al71 Alendronate, ibandronate, 
risedronate
45 939 (59.6) At 1 year, At 2 years, At 3 years,
58% (alendronate) 48% (alendronate) 42% (alendronate)
58% (ibandronate) 50% (ibandronate) 46% (ibandronate)
57% (isedronate) 47% (risedronate) 43% (risedronate)
Modi et al75 Alendronate, ibandronate, 
risedronate
37 886 (74.1) Achieving MPR ≥80% 
= 31.7%
Netelenbos et al76 Alendronate 105 506 91%
Table 3 Continued 
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upper gastrointestinal problems,51 tobacco use,27 rheu-
matoid arthritis,62 86 national insurance,63 hormone 
replacement therapy,70 clinical service use,79 mental 
disorder,104 diabetes and co-payments,102 104 were 
mentioned as determinants of persistence and adher-
ence. The relationship of these determinants to 
patients’ persistence and adherence to medication is 
described below.
Reference Medication
Population (mean 
age) Compliance, mean MPR
−69.2
Olsen et al77 Alendronate, etidronate 47 176 (70.3) Achieving MPR <50% 
= 28.4%
Achieving MPR 50% to 
79% = 11.8%
Achieving MPR ≥80% 
= 59.8%
Penning-van Beest et 
al81
Alendronate, risedronate 8822 (69.4) At 3 months, At 6 months, achieving 
MPR ≥80%
At 1 year,
Achieving an 
MPR ≥80%
Daily = 60.3% Achieving MPR ≥80%,
Daily=72.8% Weekly = 70.8% Daily = 50.2%
Weekly=80.0% Weekly = 64.3%
Penning-van Beest et 
al82
Alendronate, risedronate 8822 (n/a) Achieving MPR ≥80% 
= 58%
Rabenda et al83 Alendronate 54 807 (n/a) 64.70%
Recker et al84 Alendronate, risedronate 211 319 (n/a) 54% (daily regimen)
65% (weekly regimen)
Richards et al86 Alendronate, risedronate 573 (68.7) 69%
Sampalis et al90 Alendronate, ibandronate, 
risedronate
636 114 (72) 72%
Siris et al93 Alendronate, risedronate 35 357 (65.3) Achieving MPR ≥80% 
= 43%
Siris et al94 Alendronate, ibandronate, 
risedronate
460 584 (63.6) 53.50%
Soong et al95 Alendronate 32 604 (72.44) At 1 month, At 2 months, At 1 year,
Achieving MPR ≥80% 
= 87.6%
Achieving MPR ≥80% 
= 61.8%
Achieving MPR ≥80% 
= 28.2%
Sunyecz et al97 Alendronate, risedronate 32 944 (64.3) 55%
Tafaro et al98 Alendronate, clodronate, 
ibandronate, risedronate
6390 (n/a) 53% (daily regimen)
70% (weekly regimen)
Wang et al101 Alendronate, ibandronate, 
risedronate
522 287 (n/a) Achieving MPR <33% 
= 41.1%
Achieving MPR 34% to 
65% = 21.5%
Achieving MPR >66% 
= 37.3%
Weycker et al104 Alendronate, ibandronate, 
risedronate
644 (65.9) 57%
Yeaw et al105 Alendronate 10 268 (56.9) *60%
Ibandronate
Yood et al106 Alendronate, etidronate 176 (63.3) 70.70%
Ziller et al108 Alendronate 268 568 (63.3) 33% (alendronate 
10 mg)
57% (alendronate 
70 mg)
*Mean Proportion of Days Covered (PDC).
MPR, medication possession ratio.
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In the studies that have reported prior BMD test as a 
determinant factor, patients who have undergone prior 
BMD test before receiving medications have higher 
persistence and adherence compared with those who 
have not.20 30 39 48 70 Moreover, weekly oral bisphospho-
nates medication users had significantly higher mean 
persistence than those daily users.22 24 31 38–43 45 46 49 51–54 
63 64 78 80 81 83 86 91 92 97 99 100 102 103 107 108 Before decreasing 
at ages 80 and above a number of studies have reported 
higher persistence and adherence at older ages than 
younger ages.27 36 38 40 42 46–49 51 53 61 63 69 70 73 76 77 80 81 87 88 91 
93 94 99 102 104 107 Similarly, the number of co-medications 
being received at baseline was associated with a margin-
ally greater risk of discontinuing.40 69 77 88 91 93 Compared 
with male users of oral BP medications, female users were 
at lower odds of achieving adherence.51 60 62 69 76 77 88 92 99
dIsCussIOn
This review summarises patient persistence and adher-
ence and their determinants with oral bisphosphonates 
in the treatment of osteoporosis in real-world settings. 
A total of 89 studies, undertaken in the USA, Canada, 
Europe, Asia and Australia were used to collect informa-
tion on the real-world persistence and adherence with 
oral bisphosphonates for the treatment of osteoporosis. 
The analyses of these data suggest that patient persistence 
and adherence rates to oral bisphosphonates reduced 
over time following initial prescription. For example, 
the overall mean persistence of oral bisphosphonates 
at 6 months, 1 year and 2 years post-index ranged from 
34.8% to 71.3%, 17.6% to 74.8% and 12.9% to 60.6%, 
respectively. Dosing frequency appeared to affect 
persistence, with 6 month persistence of oral bisphospho-
nates with daily, weekly and monthly medication ranging 
between 27% and 45.5%, 45.7% and 72% and 56.8% and 
56.8%, respectively. The findings of this current review 
were similar to that reported by Cramer et al who found 
1 year persistence to bisphosphonate therapy ranged 
between 17.9% to 78.0%.16 The review by Cramer and 
colleagues also reported that patients prescribed weekly 
oral bisphosphonates exhibited better persistence than 
those prescribed daily oral bisphosphonates (35.7% to 
69.7% vs 26.1% to 55.7%).
High adherence rates of oral bisphosphonates may also 
lead to the most effective way of improving the benefit 
of these medications. For example, evidence suggests 
that the 2 year probability of fracture in females with 
osteoporosis may only begin to decrease as MPR exceeds 
50%, and notably so after it exceeds 75%.93 Across all 
included studies that reported MPR at 6and 12 months, 
the proportion of patients adherent to medication varied 
from 31.7% to 72.0% and 55.6% to 90.0%, respectively. 
Mean medication possession ratio ranged from 0.59 to 
0.81 (weekly) and 0.46 to 0.64 (daily), which are similar 
to the findings of a previous systematic review.16
Poor persistence and adherence to oral bisphospho-
nates, particularly in chronic asymptomatic disease such as 
osteoporosis, may compromise the clinical and economic 
effects of this class of medications among patients. In 
this review, 32 studies reported ≥50% persistence and 
adherence of alendronate, risedronate, etidronate and 
clodronate.23 25 26 34–37 39 41 42 46 51 53 60 61 66 67 71 76 78 81–84 87 92 
94 95 98 104 106 108 The remaining 57 studies reported ≤50% 
of persistence or adherence. The variation of patient 
persistence and adherence to medication across studies 
may be due to a number of factors and the healthcare 
system of the countries included within this review. Age27 
36 38 40 42 46–49 51 53 61 63 69 70 73 76 77 80 81 87 89 91 93 94 99 102 104 107 
and medication dosing and frequency22 24 31 38–43 45 46 49 
51–54 63 64 78 80 81 83 86 91 92 97 99 100 102 103 107 108 as a determi-
nant factor of osteoporosis was reported by 29 and 32 
studies, respectively. The studies included also indicated 
that older patients were more likely to achieve higher 
persistence and adherence to oral bisphosphonates and 
that daily users of oral bisphosphonates medications 
have lower persistence and adherence than weekly users. 
Strengths and limitations to this review are acknowledged 
by the authors. This review involved a systematic and 
rigorous search for studies relating to patient persistence 
and adherence using real-world data. Measuring adher-
ence and persistence based on real-world data is benefi-
cial as it captures the timelines and frequency of refilling 
and thus measures the continuity of medication use.110 
Database-derived persistence and adherence assessment 
carries the advantage of being objective, quantifiable and 
simple.111 Despite these strengths, it is also important 
to consider the following limitations. First, the calcula-
tion of persistence and adherence across the studies was 
heterogeneous. As a result, it was not possible to inferen-
tially compare these studies with each other. Second, the 
calculation of persistence and adherence provided in the 
studies may not be true values. For example, billing and 
coding errors may occur because data for these studies 
were obtained from patients in unrestricted ‘real world 
clinical settings’ primarily for administrative purposes.16 
Collection and refilling of medication by patients does 
not guarantee that this medication was taken as directed, 
or at all. Third, although there are data for persistence 
and adherence of oral bisphosphonates from studies 
carried out from different geographical locations, it 
was not possible to identify any trends between the data 
and countries. Fourth, it is very difficult to capture the 
specific reasons for treatment discontinuation from 
prescription-driven or medical claim data rather than 
patient-derived data. The current review excluded data 
from randomised controlled trials to better reflect patient 
behaviour in the general osteoporosis population in real-
life clinical practice. However, the exclusion of alternative 
designs such as open-label extension studies may infer an 
element of publication bias.
Additional studies are required to examine patient 
persistence or adherence in osteoporosis, including 
synthesis of qualitative studies to examine the reasons 
for discontinuation and real-world studies to examine 
healthcare resource use associated with osteoporosis 
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medication in relation to adherence and persistence. As 
osteoporosis is a chronic disease, clinicians should not 
only take into consideration the efficacy and side effects 
of medications when deciding on treatment options, but 
also ensure that realistic patient expectations from treat-
ment are set through patient education and counselling. 
The patient’s lifestyle should also be considered as this is 
likely to impact adherence and persistence with osteopo-
rosis therapy.
COnClusIOns
This review has summarised patient persistence and 
adherence to oral bisphosphonates from a quality assessed 
studies that have used real-world data. The findings of 
this review suggest that real-world patient persistence and 
adherence with oral bisphosphonates medications is often 
poor and drops notably over time following the initial 
prescription of oral medications. However, adherence 
and persistence tended to be better in older patients and 
in patients who were prescribed weekly, rather than daily 
medications. To maximise adherence and persistence to 
oral bisphosphonates, it is important to consider their 
possible determinants including medication type and 
frequency, hospitalisation, age, history of fractures, race/
ethnicity, gender, educational status and income as this 
may help to improve the health outcomes of patients with 
osteoporosis.
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